<DOC>
	<DOCNO>NCT00667823</DOCNO>
	<brief_summary>The main objective AC 055 303/SERAPHIN OL study , follow AC 055 302/SERAPHIN study , assess long-term safety tolerability ACT 064992 patient symptomatic PAH .</brief_summary>
	<brief_title>Clinical Study Assess Long-term Safety Tolerability ACT 064992 Patients With Symptomatic Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Signed informed consent prior initiation studymandated procedure . Patients pulmonary arterial hypertension complete eventdriven study , AC 055 302/SERAPHIN , Patients experience clinical worsening PAH AC 055 302/SERAPHIN write approval roll study obtain Sponsor . Women childbearing potential must negative pretreatment serum pregnancy test must use reliable method contraception study treatment least 28 day study treatment termination . Any major violation protocol AC 055 302/SERAPHIN . Pregnancy breastfeed . AST and/or ALT &gt; 3 time upper limit normal range . Any known factor disease might interfere treatment compliance , study conduct interpretation result , drug alcohol dependence psychiatric disease . Known hypersensitivity ACT 064992 excipients .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SERAPHIN</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>ACT-064992</keyword>
</DOC>